January 26, 2015 - Enlivex Therapeutics , a Hadasit Bio-Holdings portfolio company, today announced that the European Medicines Agency has granted orphan drug status to the Company's lead product candidate, ApoCell, for the prevention of Graft-versus-host Disease . Previously, ApoCell received orphan drug designation from the U.S. Food & Drug Administration .
http://ift.tt/1Db3j9c
http://ift.tt/1Db3j9c
No comments:
Post a Comment